Unraveling the genetic landscape of susceptibility to multiple primary cancers
With advances in cancer screening and treatment, there is a growing population of cancer survivors who may develop subsequent primary cancers. While hereditary cancer syndromes account for only a portion of multiple cancer cases, we sought to explore the role of common genetic variation in susceptibility to multiple primary tumors. We conducted a cross-ancestry genome-wide association study (GWAS) and transcriptome-wide association study (TWAS) of 10,983 individuals with multiple primary cancers, 84,475 individuals with single cancer, and 420,944 cancer-free controls from two large-scale studies. Our GWAS identified six lead variants across five genomic regions that were significantly associated (p < 5 × 10<sup>-8</sup>) with the risk of developing multiple primary tumors (overall and invasive) relative to cancer-free controls (at 3q26, 8q24, 10q24, 11q13.3, and 17p13). We also found one variant significantly associated with multiple cancers when compared with single cancer cases (at 22q13.1). Multi-tissue TWAS detected associations with genes involved in telomere maintenance in two of these regions (ACTRT3 in 3q26 and SLK and STN1 in 10q24) and the development of multiple cancers. Additionally, the TWAS also identified several novel genes associated with multiple cancers, including two immune-related genes, IRF4 and TNFRSF6B. Telomere maintenance and immune dysregulation emerge as central, common pathways influencing susceptibility to multiple cancers. These findings underscore the importance of exploring shared mechanisms in carcinogenesis, offering insights for targeted prevention and intervention strategies.
Authors
- Jovia L. Nierenberg (ORCID: https://orcid.org/0000-0003-2376-6714)
- Stacey Alexeeff (ORCID: https://orcid.org/0000-0001-8988-6976)
- Laurel A. Habel (ORCID: https://orcid.org/0000-0002-7230-587X)
- Lawrence H. Kushi (ORCID: https://orcid.org/0000-0001-9136-1175)
- John S. Witte (ORCID: https://orcid.org/0000-0003-0146-1434)
- Douglas A. Corley (ORCID: https://orcid.org/0000-0001-6132-5165)
- Lori C. Sakoda (ORCID: https://orcid.org/0000-0002-0900-5735)
- Rebecca E. Graff (ORCID: https://orcid.org/0000-0003-0316-8303)
- Thomas J. Hoffmann (ORCID: https://orcid.org/0000-0001-6893-4449)
- Linda Kachuri (ORCID: https://orcid.org/0000-0002-3226-4727)
- Elad Ziv (ORCID: https://orcid.org/0000-0002-2324-2884)
- Taylor B. Cavazos (ORCID: https://orcid.org/0000-0003-3537-2608)
- Pooja Middha (ORCID: https://orcid.org/0000-0001-5503-8215)
- Jie Zhang (ORCID: https://orcid.org/0000-0002-9941-1568)
- Stephen Van Den Eeden
Institutions
- Kaiser Permanente (US)
- University of California, San Francisco (US)
- Stanford Health Care (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- Stanford University (US)
Publication Details
- Journal
- Human Genetics and Genomics Advances
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1016/j.xhgg.2025.100413
- Primary Topic
- Genetic factors in colorectal cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ellison Medical Foundation
- Robert Wood Johnson Foundation
- Prostate Cancer Foundation
- Wayne and Gladys Valley Foundation
- AstraZeneca
- Kaiser Permanente
- Division of Cancer Prevention, National Cancer Institute
- Center for Strategic Scientific Initiatives, National Cancer Institute
- National Institutes of Health
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases